Nagoya Protocol: ‘a masterpiece of ambiguity’

Since the Nagoya Protocol was implemented in October 2014, lawyers, academics, and the life sciences industry broadly have been calling upon institutions such as the European Union for guidance on how to best abide by the new regulations.

Already registered?

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

Americas

Appeals court eases Teva’s headache with reversal

17 April 2026 A ruling that invalidated three of Teva's headache treatment patents has been thrown out, sending a long-running case back to the lower court.

Careers

Baker McKenzie strengthens IP bench with new German lead

16 April 2026 Fresh hire, who will take up his new role in May, brings years of expertise in pharmaceuticals and artificial intelligence to the firm’s Frankfurt practice.

Americas

Cancer drug researcher hit with suit over mutation-targeting tools

16 April 2026 The Cambridge biotech is accused of infringing six patents covering technologies used to target drug-resistant cancer mutations.